Global Flu Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Flu Vaccine market size was valued at US$ 9674 million in 2025 and is forecast to a readjusted size of US$ 13930 million by 2032 with a CAGR of 5.4% during review period.
Flu Vaccine refers to a preventive biological product that uses seasonal or potentially pandemic strains as antigens to reduce influenza-related morbidity and complications through human immunization strategies. Its technological pathways encompass inactivated and live-attenuated platforms and can switch among different manufacturing systems (egg-based, cell-culture, recombinant protein, etc.) to address antigenic drift and annual strain updates. On the regulatory side, a seasonal “recommendation–update–release” cadence has been institutionalized (as reflected in WHO position papers and national immunization guidelines), alongside a consistent framework for dosage forms, routes of administration, and eligible populations (e.g., programmatic annual vaccination for individuals ≥6 months of age). Within this framework, the vaccine functions both as a public-health intervention and as a vehicle for global supply-chain coordination and regulatory-science iteration, embodying end-to-end alignment “from strain selection, process engineering, and quality control to vaccination scenarios.”
Market Opportunities & Drivers: How can the convergence of “annual immunization + technology evolution + policy support” reshape value?The steady reinforcement of annual immunization strategies creates a predictable clinical setting for vaccination (e.g., ACIP’s routine annual recommendation for individuals ≥6 months), while the EU’s seasonal strain recommendations and pandemic fast-track pathways together establish a clear “policy–manufacture–release” supply continuum. On the technology side, cell-based and recombinant protein platforms improve adaptability to rapidly evolving strains; differentiated options such as high-dose/adjuvanted inactivated vaccines and intranasal live-attenuated formulations further segment value across populations. In the United States, authorization for intranasal vaccines to be administered at home by patients/caregivers broadens reach and adherence. Leading manufacturers are simultaneously investing in capacity and modernized processes (e.g., new high-dose Flu Vaccine units in France) to add resilience against demand swings across pandemic and seasonal scenarios. Challenges persist around strain-match uncertainty, coordination across dual seasons in different hemispheres, and ongoing commitments to cold-chain and compliance. Industry/Supply Chain: How does the closed loop from “antigen—manufacturing line—vaccination setting” to “brand—channel—service” take shape? Upstream relies on seed stocks, controlled substrates (eggs/cell lines), and excipient systems under modular quality and clinical standards. Midstream facilities with multi-platform capabilities support rapid seasonal strain switches and intra-year dual-season rotations across intercontinental networks in Europe, North America, and Australia. Representative companies include Sanofi (recombinant/high-dose portfolio), CSL Seqirus (cell-based and adjuvanted combinations with sites across the US/EU/Australia), GSK (Fluarix/FluLaval), AstraZeneca (FluMist/Fluenz intranasal LAIV), as well as active producers in China and Japan such as Hualan Bio, Changchun Institute of Biological Products (WHO-PQ), Sinovac, BCHT (intranasal LAIV), Jiangsu GDK, and KM Biologics (Japan, HA-split). Downstream, national immunization programs, pharmacies, and primary-care networks work in concert; in some markets, “home delivery and self-administration” is emerging, enriching access modes and real-world vaccination scenarios. Segmentation Trends: Which populations and settings are shaping differentiated product positions? Older adults and people with comorbidities increasingly prefer “immune-enhanced” approaches, making high-dose/adjuvanted inactivated vaccines a focal point in clinical dialogue. Pediatric and school settings value needle-free convenience and mucosal immunity; intranasal live-attenuated Flu Vaccines have accumulated long-term real-world evidence in certain markets and have expanded to home self-/caregiver administration. Markets sensitive to egg-based constraints—or seeking faster strain switches—show rising interest in cell-based and recombinant technologies. Public-health and emergency-preparedness bodies emphasize integrated readiness for both seasonal and potential pandemic use, advancing standby supply and rapid-switch mechanisms with manufacturers. Overall, a “population–platform–setting” triad is taking shape: multiple technologies coexist within the same market to meet diverse clinical needs. Regional Trends: How do North America, Europe, and Asia-Pacific each play to their strengths in strategy and supply? North America is characterized by strong alignment of guidelines and channels: CDC’s annual consensus is well established, and pharmacy networks plus home-administration options widen reach. Europe leverages EMA’s programmatic processes for seasonal composition and pandemic vaccines, emphasizing scientific consistency and rapid response. China and the broader Asia-Pacific accelerate “localized production + convergence with international norms”: some enterprises have obtained WHO-PQ and serve multiple markets, while Japanese manufacturers maintain in-country production with institutionalized annual strain updates, forming a stable regional supply. In sum, North America and Europe reinforce mature “standards–channels–compliance” linkages, while Asia-Pacific advances on “localized capacity—platform diversity—outbound supply.”Latest DevelopmentsApril 1, 2025: EMA issued Flu Vaccine composition recommendations for the 2025/2026 season, reaffirming the WHO-guided annual strain-update mechanism and providing a consistent basis for EU registrations and lot release；
September 20, 2024: AstraZeneca announced that FluMist in the United States was approved for self-/caregiver administration at home, expanding access and convenience for intranasal live-attenuated vaccination；May 13, 2024: Sanofi announced capacity expansion in France for high-dose Flu Vaccines and related capabilities, strengthening Europe’s seasonal and emergency manufacturing resilience.
This report is a detailed and comprehensive analysis for global Flu Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Flu Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (USD/Doses), 2021-2032
Global Flu Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (USD/Doses), 2021-2032
Global Flu Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Doses), and average selling prices (USD/Doses), 2021-2032
Global Flu Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (M Doses), and ASP (USD/Doses), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Flu Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Flu Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, CSL, GSK, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, KM Biologics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Flu Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Market segment by Route of Administration
Intramuscular
Intranasal
Market segment by Application
6 Months to 3 Years
> 3 Years
Major players covered
Sanofi
CSL
GSK
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Flu Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Flu Vaccine, with price, sales quantity, revenue, and global market share of Flu Vaccine from 2021 to 2026.
Chapter 3, the Flu Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Flu Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Flu Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Flu Vaccine.
Chapter 14 and 15, to describe Flu Vaccine sales channel, distributors, customers, research findings and conclusion.